|
|
 Previous Article | Table of Contents | Next Article 
Preparation and characterization of an intravenous solution of IgG from
human immunodeficiency virus-seropositive donors
LM Cummins, KJ Weinhold, TJ Matthews, AJ Langlois, CF Perno, RM Condie and JP Allain
Abbott Laboratories, Diagnostic Division, Abbott Park, IL 60064.
An intravenous solution of 99% pure globulin (hyperimmune IgG, HIVIG) was
obtained from pooled plasma of selected human immunodeficiency virus
(HIV-1)-seropositive asymptomatic donors with greater than 400
CD4+/microliters cells per microliter and a high titer of antibody to HIV-1
p24 protein. HIVIG had high titers of antibody to p24, glycoprotein 41
(gp41), and gp120, group-specific neutralizing activity, and binding to the
gp120 hypervariable loop region. It inhibited syncytia formation. At low
concentration, it enhanced viral production of HIV-1 in infected peripheral
blood monocytes but was inhibitory at higher concentration. HIVIG directed
group-specific antibody-dependent cellular cytotoxicity against
HIV-infected targets. For a period of 6 to 28 months, plasma donors kept
stable antibody titers and had a 1.0% decrease in CD4+ cells per month. One
gram per kilogram HIVIG injected in two juvenile chimpanzees was well
tolerated and did not transmit HIV, as measured by negative cell culture,
IgM immune response to HIV proteins, and polymerase chain reaction. The
mean half-life of HIV-1 p24 antibody was 15 days. These preliminary data
suggest that HIVIG is a safe product suitable for clinical trial in
HIV-1-infected individuals.
Volume 77,
Issue 5,
pp. 1111-1117,
03/01/1991
Copyright © 1991 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
X. Yang, V. Tomov, S. Kurteva, L. Wang, X. Ren, M. K. Gorny, S. Zolla-Pazner, and J. Sodroski
Characterization of the Outer Domain of the gp120 Glycoprotein from Human Immunodeficiency Virus Type 1
J. Virol.,
December 1, 2004;
78(23):
12975 - 12986.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Choi, V. S. Chhabra, Q. H. Nguyen, B. J. Ank, E. R. Stiehm, and R. L. Roberts
Interleukin-15 Enhances Cytotoxicity, Receptor Expression, and Expansion of Neonatal Natural Killer Cells in Long-Term Culture
Clin. Vaccine Immunol.,
September 1, 2004;
11(5):
879 - 888.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Pantophlet, I. A. Wilson, and D. R. Burton
Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design
J. Virol.,
May 15, 2003;
77(10):
5889 - 5901.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. G. Hemming
Use of Intravenous Immunoglobulins for Prophylaxis or Treatment of Infectious Diseases
Clin. Vaccine Immunol.,
September 1, 2001;
8(5):
859 - 863.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Veljkovic, R. Metlas, D. Jevtovic, and W. W. Stringer
The Role of Passive Immunization in HIV-Positive Patients : A Case Report
Chest,
August 1, 2001;
120(2):
662 - 666.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Scharf, H. Golding, L. R. King, N. Eller, D. Frazier, B. Golding, and D. E. Scott
Immunoglobulin G3 from Polyclonal Human Immunodeficiency Virus (HIV) Immune Globulin Is More Potent than Other Subclasses in Neutralizing HIV Type 1
J. Virol.,
July 15, 2001;
75(14):
6558 - 6565.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
T. Beaumont, S. Broersen, A. van Nuenen, H. G. Huisman, A.-M. de Roda Husman, J. L. Heeney, and H. Schuitemaker
Increased Neutralization Sensitivity and Reduced Replicative Capacity of Human Immunodeficiency Virus Type 1 after Short-Term In Vivo or In Vitro Passage through Chimpanzees
J. Virol.,
September 1, 2000;
74(17):
7699 - 7707.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
L. M. Mofenson, J. S. Lambert, E. R. Stiehm, J. Bethel, W. A. Meyer, J. Whitehouse, J. Moye, P. Reichelderfer, D. R. Harris, M. G. Fowler, et al.
Risk Factors for Perinatal Transmission of Human Immunodeficiency Virus Type 1 in Women Treated with Zidovudine
N. Engl. J. Med.,
August 5, 1999;
341(6):
385 - 393.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. M. Stamatos, J. R. Mascola, V. S. Kalyanaraman, M. K. Louder, L. M. Frampton, D. L. Birx, and T. C. VanCott
Neutralizing Antibodies from the Sera of Human Immunodeficiency Virus Type 1-Infected Individuals Bind to Monomeric gp120 and Oligomeric gp140
J. Virol.,
December 1, 1998;
72(12):
9656 - 9667.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. H. Nguyen, R. L. Roberts, B. J. Ank, S.-J. Lin, C. K. Lau, and E. R. Stiehm
Enhancement of Antibody-Dependent Cellular Cytotoxicity of Neonatal Cells by Interleukin-2 (IL-2) and IL-12
Clin. Vaccine Immunol.,
January 1, 1998;
5(1):
98 - 104.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
D. Burton, J Pyati, R Koduri, S. Sharp, G. Thornton, P. Parren, L. Sawyer, R. Hendry, N Dunlop, P. Nara, et al.
Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody
Science,
November 11, 1994;
266(5187):
1024 - 1027.
[Abstract]
[PDF]
|
|
|
|
|
